Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Net Margin (2016 - 2025)

Karyopharm Therapeutics' Net Margin history spans 14 years, with the latest figure at 264.64% for Q4 2025.

  • For Q4 2025, Net Margin rose 36568.0% year-over-year to 264.64%; the TTM value through Dec 2025 reached 2.5%, up 5017.0%, while the annual FY2025 figure was 2.5%, 5017.0% up from the prior year.
  • Net Margin reached 264.64% in Q4 2025 per KPTI's latest filing, up from 75.21% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 299.84% in Q4 2023 to a low of 246.84% in Q1 2021.
  • Average Net Margin over 5 years is 59.58%, with a median of 92.01% recorded in 2023.
  • Peak YoY movement for Net Margin: skyrocketed 41460bps in 2023, then tumbled -40088bps in 2024.
  • A 5-year view of Net Margin shows it stood at 54.44% in 2021, then crashed by -311bps to 114.76% in 2022, then soared by 361bps to 299.84% in 2023, then plummeted by -134bps to 101.04% in 2024, then skyrocketed by 362bps to 264.64% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Net Margin are 264.64% (Q4 2025), 75.21% (Q3 2025), and 98.22% (Q2 2025).